Active	Status	Sponsor type	Region	Phase	Filter
6 Active 0 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

6 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Encarnacion, Carlos
CLASP IID, NCT03706833: Edwards PASCAL /IIF Pivotal Clinical Trial	Recruiting	N/A	1247	Europe, Canada, US	Edwards PASCAL System, Transcatheter Mitral Valve repair (TMVr), Abbott Mitraclip System	Edwards Lifesciences	Degenerative Mitral Valve Disease, Mitral Regurgitation, Mitral Insufficiency, Functional Mitral Regurgitation	01/25	04/30
BTX-BCI-016-PRT, NCT04875351: Breast Cancer Index (BCI) Registry	Active, not recruiting	N/A	3465	US	Breast Cancer Index (BCI) Risk of Recurrence & Extended Endocrine Benefit Test, Breast Cancer Index (BCI) Test	Biotheranostics, Inc.	Breast Cancer	12/28	12/28
FLEX, NCT03053193: MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles	Recruiting	N/A	30000	Europe, Canada, US, RoW	MammaPrint, BluePrint, and Full-Genome Testing, MammaPrint, BluePrint	Agendia	Breast Cancer	04/37	12/37
Fonseca, Laura
ELEVAATE, NCT05856331: Study of SAR447537 (INBRX-101) Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema	Active, not recruiting	2	99	Europe, US, RoW	SAR447537, Zemaira, Respreeza	Sanofi	Alpha 1-Antitrypsin Deficiency, Emphysema	08/25	10/25
BTX-BCI-016-PRT, NCT04875351: Breast Cancer Index (BCI) Registry	Active, not recruiting	N/A	3465	US	Breast Cancer Index (BCI) Risk of Recurrence & Extended Endocrine Benefit Test, Breast Cancer Index (BCI) Test	Biotheranostics, Inc.	Breast Cancer	12/28	12/28
FLEX, NCT03053193: MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles	Recruiting	N/A	30000	Europe, Canada, US, RoW	MammaPrint, BluePrint, and Full-Genome Testing, MammaPrint, BluePrint	Agendia	Breast Cancer	04/37	12/37